Interview with Charles Woler, CEO, Endotis Pharma
Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research…
Endotis Pharma
Last updated: 13.02.2014
Address: 102 avenue Gaston Roussel
93230 Romainville France
Tel: +33 (0)1 48 46 43 91
Company description
Endotis Pharma is a biopharmaceutical company dedicated to the discovery and development of small-glyco drugs (SGDs, heparin / heparan sulphate mimetics) for use in thrombosis, oncology and a range of other indications with several potential blockbuster drugs. Founded in february 2003, Endotis is a privately held company which currently employs 34 people between sites in Paris and Lille.
Endotis’ business model is to develop antithrombotic drugs in man until proof-of principle (oral anticoagulants) or Phase IIb dose finding (parenteral antithrombotics), and then partner them; while in other therapeutic areas such as oncology, partnering could take place once proof of concept in animal is demonstrated.
Products and services
Endotis has three main areas of activity:
– A derisked thrombosis franchise of heparin-derived synthetic oligosaccharides
– An oncology pipeline consisting of heparan sulfate mimetics
– A drug discovery engine: unique know-how from discovery to manufacturing of small-glyco drugs (SGDs) with range of applications
Interviews
Related
France / Germany Production Alliance Falters; Sanofi Vaccine Enters Phase III Trials; Valneva Still in the Vaccine Race
The latest news from French pharma, including why President Emmanuel Macron’s initiative to bring medical…
COVID-19 Vaccines / Valneva: A Success Story for France?
While Big Pharma companies like Pfizer, Janssen and AstraZeneca, have grabbed the headlines over the past year for…
France / ‘Humiliation’ & the Sanofi-Pfizer Vaccine Deal; AntiVax Struggles; Servier’s Neurology Push
The latest from French pharma where Sanofi has inked a deal to produce 125 million doses of Pfizer’s COVID-19…
France / Mid-2021 for Sanofi COVID-19 Vaccine; 1 Million Domestic Cases; Ipsen Growth
A roundup of the latest stories from French pharma, including the progress of Sanofi’s COVID-19 vaccine, how…
News Roundup / French Pharma August 2020
A roundup of some of the latest from French pharma, including Sanofi’s bumper Prinicipia deal, how Unither’s…
M&A / Sanofi Buys Principia for USD 3.7 Billion as Part of Specialty Pivot
Sanofi has agreed a deal to buy out its partner, US biotech company Principia Biopharma for USD 3.7 billion in…
Sanofi / Thomas Triomphe Appointed Executive Vice President of Vaccines Unit
With former head David Loew moving to the CEO position at Ipsen, Sanofi appointed French national Thomas Triomphe…
Mid-Cap Strategies / LFB USA CEO Optimistic on Hemophilia Launches Amid COVID Crisis
French firm LFB is targeting the lucrative US market with its hemophilia products and recently received two FDA…
Sanofi / USD 679 Million Investment in French Vaccine Manufacturing
French pharma giant Sanofi is pivoting its focus to invest more heavily in vaccines with a plan to invest USD 679…
Ipsen / New CEO as David Loew Makes Switch From Sanofi Pasteur
David Loew, formerly executive vice president of Sanofi Pasteur, Sanofi’s vaccines division, was appointed…
Europe / A New Approach to Health Crises in France & Germany
Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would…
COVID-19 Vaccine / Sanofi CEO Paul Hudson Commits to "Bring a Solution to Everybody, Everywhere"
In a recent interview with Financial Times, Sanofi CEO Paul Hudson set out to clarify some recent comments that the…
